Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma
Sundar Jagannath(Mount Sinai Hospital), Peter M. Voorhees(Levine Cancer Institute), Saad Z. Usmani(Memorial Sloan Kettering Cancer Center), Deepu Madduri(Johnson & Johnson (United States)), Mounzer Agha(Dana-Farber Cancer Institute), Adam D. Cohen(Penn Center for AIDS Research), Nikoletta Lendvai(Centro de Investigación del Cáncer), Vicki Plaks(Johnson & Johnson (United States)), Samir Parekh(The Ohio State University Wexner Medical Center), Alexander M. Lesokhin(Memorial Sloan Kettering Cancer Center), Mythili Koneru(Cooper Medical School of Rowan University), Adriana Rossi(Icahn School of Medicine at Mount Sinai), Jesús G. Berdeja(Tennessee Oncology), Abhinav Deol(Wayne State University), Noopur Raje(Massachusetts General Hospital), Arnob Banerjee(Johnson & Johnson (United States)), Andrzej Jakubowiak(University of Chicago Medical Center), Rocío Montes de(Johnson & Johnson (United States)), Binod Dhakal(Medical College of Wisconsin), Thomas G. Martin(University of California San Francisco Medical Center), Myo Htut(City of Hope), Alex Lieberman-Cribbin(Icahn School of Medicine at Mount Sinai), Jordan M. Schecter(Centro de Investigación del Cáncer), Yi Lin, Huijun Li(Zhejiang University), Rui Wang(Sun Yat-sen University), Tamar Lengil(Johnson & Johnson (United States)), Muhammad Akram(Government College University, Faisalabad), Jieqing Zhu(490 BioTech (United States)), Octavio Costa Filho(490 BioTech (United States)), Nitin Patel(Centro de Investigación del Cáncer), Jessica J. Liegel(Beth Israel Deaconess Medical Center), Huabin Sun(Johnson & Johnson (United States))
Cited by 107
Related Papers
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k